A61K 40/4241
P53
Official title: {p53}
A61K40/4241 (P53) appears on 22 US grants and 62 published applications in this corpus.
Search patents in A61K- Granted patents
- 22
- Published applications
- 62
- Assignees
- 42
- Inventors
- 135
- Latest grant
- 1 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2002 | 0 | 2 |
| 2003 | 1 | 8 |
| 2004 | 1 | 3 |
| 2005 | 0 | 1 |
| 2006 | 0 | 3 |
| 2007 | 0 | 2 |
| 2008 | 1 | 1 |
| 2009 | 0 | 1 |
| 2010 | 1 | 3 |
| 2011 | 1 | 0 |
| 2012 | 1 | 2 |
| 2013 | 1 | 0 |
| 2014 | 1 | 2 |
| 2015 | 1 | 2 |
| 2016 | 1 | 0 |
| 2017 | 0 | 1 |
| 2018 | 2 | 2 |
| 2019 | 0 | 0 |
| 2020 | 0 | 4 |
| 2021 | 1 | 3 |
| 2022 | 3 | 6 |
| 2023 | 0 | 7 |
| 2024 | 2 | 5 |
| 2025 | 3 | 2 |
| 2026 | 1 | 2 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- T cell receptors recognizing R273C or Y220C mutations in P531 Sep 2026US 12,721,890 B2The United States of America, as represented by the Secretary, Department of Health and Human Services
- Dendritic cell preparation and preparation method thereof14 Oct 2025US 12,440,565 B1Zsky Biotech Inc.
- Methods of obtaining tumor-specific T cell receptors15 Jul 2025US 12,358,967 B2Hryz (Guangzhou) Biotech Co.
- Methods for selectively expanding cells expressing a TCR with a murine constant region18 Feb 2025US 12,227,554 B2The United States of America, as represented by the Secretary, Department of Health and Human Services
- Dendritic cell tumor vaccine and uses thereof24 Sep 2024US 12,097,259 B2Shenzhen Frontiergate Biotechnology Co., Ltd
- T cell receptors targeting tp53 hotspot mutations and uses thereof13 Aug 2026US 2026/0232801 A1Memorial Hospital for Cancer and Allied Diseases
- Allogeneic dendritic cell (allodc) tumor vaccine, and preparation method and use thereof16 Apr 2026US 2026/0102493 A1Shenzhen Frontiergate Biotechnology Co., Ltd
- Targeting common somatic mutations in breast cancer with neo-antigen specific adoptive t cell therapy23 Oct 2025US 2025/0325668 A1Baylor College of Medicine
- Models for predicting mutant p53 fitness and their implications in cancer therapy16 Oct 2025US 2025/0322927 A1Icahn School of Medicine at Mount Sinai
- T cell receptor recognizing r175h mutation in p53 and its application19 Dec 2024US 2024/0415886 A1
Most cited
By later US patents
- HLA class I A2 tumor associated antigen peptides and vaccine compositions58US 6,602,510 B1Epimmune Inc. · 2003
- P53-specific T cell receptor for adoptive immunotherapy41US 6,770,749 B2City of Hope · 2004
- In vivo activation of tumor-specific cytotoxic T cells25US 7,402,314 B2The Scripps Research Institute · 2008
- Intrathecal and intratumoral superantigens to treat malignant disease18US 7,776,822 B2Jenquest · 2010
- HLA-A2 tumor associated antigen peptides and compositions12US 9,913,884 B2Ose Pharma International SA · 2018